p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma
Abstract
P16 and P14ARF are two tumor suppressors encoded by the locus ink4a-arf which is frequently deleted in human tumors. Recent experiments performed with mouse embryonic fibroblasts have shown that P14ARF is an upstream regulator of the P53 pathway. This raises the question as to whether in human tumors the loss of p14arf and mutation of p53 are mutually exclusive events which segregate with genetic alterations at other loci. To examine this question we performed a multigenic analysis on 29 gliomas. We analysed p53 and p14arf in relation with five other genetic loci encoding the most frequently mutated genes in human gliomas: cdkn2a, mdm2, egfr, pten and the chromosomal regions 10q23.3 and 10q25-26. Our study shows for the first time that p53 mutations and p14arf deletions appear mutually exclusive in human glioblastoma, suggesting that they may be functionally redundant in glioma tumorigenesis. The P53 pathway is, therefore, disrupted in 81.8% of malignant gliomas (WHO grades III and IV), either by mutation of the p53 gene (31.8%) or by p14arf deletion (54.5%). These tumors further showed MDM2 overexpression (9.1%), egfr oncogene amplification/egfr overexpression (50%), pten mutations (27.3%) and loss of heterozygosity (LOH) at the chromosomal regions 10q23.3 (86.4%) and 10q25-26 (100%). These alterations did not segregate with p53 mutations or p14arf deletions, while p14arf and cdkn2a were always deleted.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
CDKN2A/ARF and TP53 are rarely co-deregulated, suggesting redundancy in the effects of their loss on glioblastoma malignancy.
“CDKN2A/ARF and TP53 are rarely co-deregulated, suggesting redundancy in the effects of their loss on GBM malignancy [39,40].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [39]
Cites
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566 · see citing works
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · see citing works
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
Oliner, J. D., Pietenpol, J. A., Thiagalingam, S., Gyuris, J., Kinzler, K. W., & Vogelstein, B. (1993) · Nature · doi:10.1038/362857a0 · Cited by 1,447 · see citing works
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245 · see citing works
A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.
Nishikawa, R., Ji, X.-D., Harmon, R. C., Lazar, C. S., Gill, G. N., Cavenee, W. K., & Huang, H. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7727 · Cited by 936 · see citing works
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus
Kamb, A., Shattuck-Eidens, D. M., Eeles, R. A., Liu, Q., Gruis, N. A., Ding, W., Hussey, C. E., Tran, T., Miki, Y., Weaver-Feldhaus, J., et al. (1994) · Nature Genetics · doi:10.1038/ng0994-22 · Cited by 855 · see citing works
Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724 · see citing works
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
Cairns, P., Polascik, T. J., Eby, Y. J., Tokino, K., Califano, J. A., Merlo, A. U., Mao, L., Herath, J. F., Jenkins, R. B., Westra, W. H., et al. (1995) · Nature Genetics · doi:10.1038/ng1095-210 · Cited by 626 · see citing works
Self-citationE1A signaling to p53 involves the p19ARFtumor suppressorPreprint
de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S.-Y., Ferbeyre, G., Samuelson, A. V., Prives, C. L., Roussel, M. F., Sherr, C. J., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.15.2434 · Cited by 607 · see citing works
Interaction between the retinoblastoma protein and the oncoprotein MDM2
Xiao, Z.-X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J. W., Sellers, W. R., & Livingston, D. M. (1995) · Nature · doi:10.1038/375694a0 · Cited by 586 · see citing works
Reifenberger, G., Liu, L., Ichimura, K., Schmidt, E., & Collins, V. P. (1993) · PubMed · Cited by 562 · see citing works
(1997) · PubMed · Cited by 512 · see citing works
Mollenhauer, J., Wiemann, S., Scheurlen, W. G., Korn, B., Hayashi, Y., Wilgenbus, K. K., von Deimling, A., & Poustka, A. (1997) · Nature Genetics · doi:10.1038/ng0997-32 · Cited by 446 · see citing works
CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Schmidt, E., Ichimura, K., Reifenberger, G., & Collins, V. P. (1994) · PubMed · Cited by 436 · see citing works
p300/MDM2 complexes participate in MDM2-mediated p53 degradation
Grossman, S. R., Perez, M., Kung, A. L., Joseph, M., Mansur, C., Xiao, Z.-X., Kumar, S., Howley, P. M., & Livingston, D. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80140-9 · Cited by 414 · see citing works
Complex structure and regulation of the P16 (MTS1) locus.
Stone, S., Jiang, P., Dayananth, P., Tavtigian, S. V., Katcher, H. L., Parry, D., Peters, G., & Kamb, A. (1995) · PubMed · Cited by 383 · see citing works
Zhang, Y., & Xiong, Y. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80351-2 · Cited by 347 · see citing works
PTEN mutations in gliomas and glioneuronal tumors
Duerr, E., Rollbrocker, B., Hayashi, Y., Peters, N., Meyer‐Puttlitz, B., Louis, D. N., Schramm, J., Wiestler, O. D., Parsons, R. E., Eng, C., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201756 · Cited by 345 · see citing works
Mao, L., Merlo, A. U., Bedi, G. C., Shapiro, G. I., Edwards, C. D., Rollins, B. J., & Sidransky, D. (1995) · PubMed · Cited by 329 · see citing works
Self-citationIchimura, K., Bondesson, M., Goike, H., Schmidt, E., Moshref, A., & Collins, V. P. (2000) · PubMed · Cited by 282 · see citing works
Molecular pathways in the formation of gliomas
von Deimling, A., Louis, D. N., & Wiestler, O. D. (1995) · Glia · doi:10.1002/glia.440150312 · Cited by 245 · see citing works
CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines.
He, J., Allen, J. R., Collins, V. P., Allalunis‐Turner, M. J., Godbout, R., Day, R. S., & James, C. D. (1994) · PubMed · Cited by 217 · see citing works
Field cancerisation and polyclonal p53 mutation in the upper aero- digestive tract
Waridel, F., Estreicher, A., Bron, L. P., Flaman, J., Fontolliet, C., Monnier, P., Frébourg, T., & Iggo, R. D. (1997) · Oncogene · doi:10.1038/sj.onc.1200812 · Cited by 179 · see citing works
Amplification and Overexpression of MDM2 in Primary (de novo) Glioblastomas
Biernat, W., Kleihues, P., Yonekawa, Y., & Ohgaki, H. (1997) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199702000-00009 · Cited by 178 · see citing works
Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas
Biernat, W., Tohma, Y., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1997) · Acta Neuropathologica · doi:10.1007/s004010050711 · Cited by 166 · see citing works
Sánchez‐Céspedes, M., Reed, A. L., Buta, M. R., Li, W., Westra, W. H., Herman, J. G., Yang, S. C., Jen, J., & Sidransky, D. (1999) · Oncogene · doi:10.1038/sj.onc.1203003 · Cited by 130 · see citing works
Association of EGFR Gene Amplification and CDKN2 (p16/MTS1) Gene Deletion in Glioblastoma Multiforme
Hayashi, Y., Ueki, K., Waha, A., Wiestler, O. D., Louis, D. N., & von Deimling, A. (1997) · Brain Pathology · doi:10.1111/j.1750-3639.1997.tb00890.x · Cited by 128 · see citing works
Gazzéri, S., Della-Valle, V., Chaussade, L., Brambilla, C., Larsen, C., & Brambilla, E. M. (1998) · PubMed · Cited by 126 · see citing works
Vonlanthen, S., Heighway, J., Tschan, M. P., Borner, M., Altermatt, H. J., Каппелер, А., Tobler, A., Fey, M. F., Thatcher, N., Yarbrough, W. G., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1202501 · Cited by 104 · see citing works
Sure, U., Rüedi, D., Tachibana, O., Yonekawa, Y., Ohgaki, H., Kleihues, P., & Hegi, M. E. (1997) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199756070-00004 · Cited by 94 · see citing works
Self-citationMaier, D., Zhang, Z., Taylor, E., Hamou, M., Gratzl, O., Meir, E. G. V., Scott, R. J., & Merlo, A. U. (1998) · Oncogene · doi:10.1038/sj.onc.1201832 · Cited by 89 · see citing works
Self-citationPTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas
Chiariello, E., Roz, L., Albarosa, R., Magnani, I., & Finocchiaro, G. (1998) · Oncogene · doi:10.1038/sj.onc.1201689 · Cited by 81 · see citing works
p53 and Brain Tumors: From Gene Mutations to Gene Therapy
Fulci, G., Ishii, N., & Meir, E. G. V. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00187.x · Cited by 79 · see citing works
Self-citationNakamura, H., Yoshida, M., Tsuiki, H., Ito, K., Ueno, M., Nakao, M., Oka, K., Tada, M., Kochi, M., Kuratsu, J., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201618 · Cited by 67 · see citing works
HUNTER, S. B., Abbott, K. L., VARMA, V. A., Olson, J. J., Barnett, D. W., & James, C. D. (1995) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199501000-00007 · Cited by 59 · see citing works
Maier, D., Comparone, D., Taylor, E., Zhang, Z., Gratzl, O., Meir, E. G. V., Scott, R. J., & Merlo, A. U. (1997) · Oncogene · doi:10.1038/sj.onc.1201209 · Cited by 56 · see citing works
Self-citationThe functional role of tumor suppressor genes in gliomas
Fueyo-Margareto, J., Gomez‐Manzano, C., Yung, W. K. A., & Kyritsis, A. P. (1998) · Neurology · doi:10.1212/wnl.51.5.1250 · Cited by 39 · see citing works
Amplification of the mdm2 gene and p53 abnormalities in uterine sarcomas
Seki, A., Kodama, J., Miyagi, Y., Kamimura, S., Yoshinouchi, M., & Kudo, T. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970926)73:1 · Cited by 35 · see citing works
Self-citationType and Frequency of p53 Mutations in Tumors of the Nervous System and Its Coverings
Kleihues, P., Ohgaki, H., Eibl, R. H., Reichel, M., Mariani, L., Gehring, M., Petersen, I., Holl, T. M., von Deimling, A., Wiestler, O. D., et al. (1994) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-85039-4_4 · Cited by 23 · see citing works
No Complementation Between TP53 or RB‐1 and v‐src in Astrocytomas of GFAP‐v‐src Transgenic Mice
Maddalena, A. S., Hainfellner, J. A., Hegi, M. E., Glatzel, M., & Aguzzi, A. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00544.x · Cited by 20 · see citing works
Self-citationBenz, C. C., & Liu, E. (1989) · Cancer treatment and research · doi:10.1007/978-1-4613-1599-5 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Glioblastoma multiforme: a review of where we have been and where we are going
Adamson, C., Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Mattox, A. K., & Bigner, D. D. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903052764 · Cited by 544 · see citing works
The p53 Pathway in Glioblastoma
Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440 · see citing works
Gliomagenesis: genetic alterations and mouse models
Holland, E. C. (2001) · Nature Reviews Genetics · doi:10.1038/35052535 · Cited by 453 · see citing works
The Molecular and Genetic Basis of Neurological Tumours
Zhu, Y., & Parada, L. (2002) · Nature Reviews. Cancer · doi:10.1038/nrc866 · Cited by 340 · see citing works
Recent Advances in the Treatment of Malignant Astrocytoma
Reardon, D. A., Rich, J. N., Friedman, H. S., & Bigner, D. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5302 · Cited by 308 · see citing works
Uhrbom, L., Dai, C., Celestino, J., Rosenblum, M. K., Fuller, G. N., & Holland, E. C. (2002) · PubMed · Cited by 286 · see citing works
Mao, H., LeBrun, D. G., Yang, J., Zhu, V. F., & Li, M. (2012) · Cancer Investigation · doi:10.3109/07357907.2011.630050 · Cited by 266 · see citing works
Development of novel targeted therapies in the treatment of malignant glioma
Rich, J. N., & Bigner, D. D. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1380 · Cited by 246 · see citing works
NFKBIA Deletion in Glioblastomas
Bredel, M., Scholtens, D. M., Yadav, A. K., Alvarez, A. A., Renfrow, J. J., Chandler, J. P., Yu, I. L. Y., Carro, M. S., Dai, F., Tagge, M. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006312 · Cited by 241 · see citing works
EGFR overexpression and radiation response in glioblastoma multiforme
Barker, F. G., Simmons, M. L., Chang, S. M., Prados, M. D., Larson, D. A., Sneed, P. K., Wara, W. M., Berger, M. S., Chen, P., Israel, M. A., et al. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01609-1 · Cited by 243 · see citing works
Naturally occurring melanomas in dogs as models for non‐ UV pathways of human melanomas
Gillard, M., Cadieu, É., Brito, C. D., Abadie, J., Vergier, B., Devauchelle, P., Degorce‐Rubiales, F., Dréano, S., Primot, A., Dorso, L., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12170 · Cited by 174 · see citing works
Glioblastoma multiforme: a review of therapeutic targets
Kanu, O. O., Mehta, A. I., Di, C., Lin, N., Bortoff, K., Bigner, D. D., Yan, H., & Adamson, D. C. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902942348 · Cited by 169 · see citing works
Glioblastoma Multiforme Oncogenomics and Signaling Pathways
Kanu, O. O., Hughes, B. D., Di, C., Lin, N., Fu, J., Bigner, D. D., Yan, H., & Adamson, C. (2009) · Clinical medicine Oncology · doi:10.4137/cmo.s1008 · Cited by 146 · see citing works
Cobbs, C., Whisenhunt, T. R., Wesemann, D. R., Harkins, L. E., Meir, E. G. V., & Samanta, M. (2003) · PubMed · Cited by 144 · see citing works
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131 · see citing works
Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth
Landen, J. W., Hau, V. S., Wang, M., Davis, T. P., Ciliax, B. J., Wainer, B. H., Meir, E. G. V., Glass, J. D., Joshi, H. C., & Archer, D. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0360 · Cited by 130 · see citing works
INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas
Tannapfel, A., Busse, C., Weinans, L., Benicke, M., Katalinic, A., Geißler, F., Hauss, J., & Wittekind, C. (2001) · Oncogene · doi:10.1038/sj.onc.1204902 · Cited by 129 · see citing works
The Arf/p53 Pathway in Cancer and Aging
Matheu, A., Maraver, A., & Serrano, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6851 · Cited by 129 · see citing works
Distinct methylation profiles of glioma subtypes
Uhlmann, K., Rohde, K., Zeller, C., Szymaś, J., Vogel, S., Marczinek, K., Thiel, G., Nürnberg, P., & Laird, P. W. (2003) · International Journal of Cancer · doi:10.1002/ijc.11175 · Cited by 114 · see citing works
Genetic and epigenetic alterations as hallmarks of the intricate road to cancer
Macaluso, M., Paggi, M. G., & Giordano, A. (2003) · Oncogene · doi:10.1038/sj.onc.1206955 · Cited by 109 · see citing works
Chakravarti, A., Delaney, M. A., Noll, E., Black, P. M., Loeffler, J. S., Muzikansky, A., & Dyson, N. J. (2001) · PubMed · Cited by 111 · see citing works
Calogero, A., Arcella, A., Gregorio, G. D., Porcellini, A., Mercola, D., Liu, C., Lombari, V., Zani, M., Giannini, G., Gagliardi, F., et al. (2001) · PubMed · Cited by 109 · see citing works
Silva, J., Silva, J. M., Domínguez, G., García, J. M., Cantos, B., Rodríguez, R., Larrondo, F. J., Provencio, M., España, P., & Bonilla, F. (2003) · The Journal of Pathology · doi:10.1002/path.1297 · Cited by 107 · see citing works
TP53 promoter methylation in human gliomas
Amatya, V. J., Naumann, U., Weller, M., & Ohgaki, H. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1041-5 · Cited by 99 · see citing works
Genetic and Biologic Progression in Astrocytomas and Their Relation to Angiogenic Dysregulation
Brat, D. J., Castellano-Sanchez, A. A., Kaur, B., & Meir, E. G. V. (2002) · Advances in Anatomic Pathology · doi:10.1097/00125480-200201000-00004 · Cited by 96 · see citing works
Wolter, M., REIFENBERGER, J., Blaschke, B., Ichimura, K., Schmidt, E., Collins, V. P., & Reifenberger, G. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.12.1170 · Cited by 97 · see citing works
Neoplastic cells are a rare component in human glioblastoma microvasculature
Rodríguez, F. J., Orr, B. A., Ligon, K. L., & Eberhart, C. G. (2012) · Oncotarget · doi:10.18632/oncotarget.427 · Cited by 86 · see citing works
Prevalence of aberrant methylation of p14ARF over p16INK4a in some human primary tumors
Domínguez, G., Silva, J., Garcia, J. M., Silva, J. M., Rodríguez, R., Muñoz, C., Chacón, I., Sanchez, R., Carballido, J., Colás, A., et al. (2003) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(03)00133-7 · Cited by 85 · see citing works
Inhibition of cell growth by EGR-1 in human primary cultures from malignant glioma
Calogero, A., Lombari, V., Gregorio, G. D., Porcellini, A., Ucci, S., Arcella, A., Caruso, R., Gagliardi, F. M., Gulino, A., Lanzetta, G., et al. (2004) · Cancer Cell International · doi:10.1186/1475-2867-4-1 · Cited by 85 · see citing works
Modulation of Cell Cycle Components by Epigenetic and Genetic Events
Macaluso, M., Montanari, M., Cinti, C., & Giordano, A. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.07.009 · Cited by 83 · see citing works
The INK4A/ARF Locus: Role in Cell Cycle Control and Apoptosis and Implications for Glioma Growth
Ivanchuk, S. M., Mondal, S., Dirks, P. B., & Rutka, J. T. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1010632309113 · Cited by 80 · see citing works
Genetic modulation of hypoxia induced gene expression and angiogenesis relevance to brain tumors
Brat, D. J. (2003) · Frontiers in bioscience · doi:10.2741/942 · Cited by 77 · see citing works
Immunohistochemical Markers for Prognosis of Ependymal Neoplasms
Korshunov, A., Голанов, А. В., & Timirgaz, V. (2002) · Journal of Neuro-Oncology · doi:10.1023/a:1016222202230 · Cited by 75 · see citing works
Array Comparative Genomic Hybridization Identifies Genetic Subgroups in Grade 4 Human Astrocytoma
Misra, A., Pellarin, M., Nigro, J. M., Smirnov, I. V., Moore, D. H., Lamborn, K. R., Pinkel, D., Albertson, D. G., & Feuerstein, B. G. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0708 · Cited by 73 · see citing works
P14ARF inhibits human glioblastoma–induced angiogenesis by upregulating the expression of TIMP3
Zerrouqi, A., Pyrzynska, B., Febbraio, M., Brat, D. J., & Van Meir, E. G. (2012) · Journal of Clinical Investigation · doi:10.1172/jci38596 · Cited by 70 · see citing works
Frank, A. J., Hernán, R., Hollander, A. B., Lindsey, J. C., Lusher, M. E., Fuller, C. E., Clifford, S. C., & Gilbertson, R. J. (2004) · Molecular Brain Research · doi:10.1016/j.molbrainres.2003.11.016 · Cited by 68 · see citing works
Genes and pathways driving glioblastomas in humans and murine disease models
Merlo, A. U. (2003) · Neurosurgical Review · doi:10.1007/s10143-003-0267-8 · Cited by 67 · see citing works
Self-citationLabuhn, M., Jones, G., Speel, E. M., Maier, D., Zweifel, C., Gratzl, O., Meir, E. G. V., Hegi, M. E., & Merlo, A. U. (2001) · Oncogene · doi:10.1038/sj.onc.1204197 · Cited by 66 · see citing works
Self-citationSánchez‐Aguilera, A., Sánchez‐Beato, M., García, J. F., Priéto, I., Pollán, M., & Piris, M. A. (2002) · Blood · doi:10.1182/blood.v99.4.1411 · Cited by 62 · see citing works
Puduvalli, V. K., Sampath, D., Bruner, J. M., Nangia, J. R., Xu, R., & Kyritsis, A. P. (2005) · APOPTOSIS · doi:10.1007/s10495-005-6078-3 · Cited by 60 · see citing works
Hoenerhoff, M. J., Hong, H. H., Ton, T.-V., Lahousse, S. A., & Sills, R. C. (2009) · Toxicologic Pathology · doi:10.1177/0192623309351726 · Cited by 58 · see citing works
Smith, I. N., & Briggs, J. M. (2016) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.25105 · Cited by 55 · see citing works
Frequent LOH at Chromosome 12q22‐23 and Apaf‐1 Inactivation in Glioblastoma
Watanabe, T., Hirota, Y., Arakawa, Y., Fujisawa, H., Tachibana, O., Hasegawa, M., Yamashita, J., & Hayashi, Y. (2003) · Brain Pathology · doi:10.1111/j.1750-3639.2003.tb00474.x · Cited by 55 · see citing works
Nicholson, S. A., Okby, N. T., Ma, K., Welsh, J. A., McMenamin, M. G., Travis, W. D., Jett, J. R., Tazelaar, H. D., Trastek, V. F., Pairolero, P. C., et al. (2001) · PubMed · Cited by 53 · see citing works
Radioresistance of human glioma spheroids and expression of HSP70, p53 and EGFr
Fedrigo, C. A., Grivicich, I., Schunemann, D. P., Chemale, I. M., dos Santos, D., Jacovas, T., Boschetti, P. S., Jotz, G. P., Filho, A. B., & da Rocha, A. B. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-156 · Cited by 52 · see citing works
Wills, K. N., Atencio, I. A., Avanzini, J. B., Neuteboom, S., Phelan, A., Philopena, J. M., Sutjipto, S., Vaillancourt, M. T., Wen, S. F., Ralston, R., et al. (2001) · Journal of Virology · doi:10.1128/jvi.75.18.8733-8741.2001 · Cited by 52 · see citing works
The status of gene therapy for brain tumors
Fulci, G., & Chiocca, E. A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.2.197 · Cited by 51 · see citing works
Self-citationTherapeutic Targets in the ARF Tumor Suppressor Pathway
Saporita, A. J., Maggi, L. B., Apicelli, A. J., & Weber, J. D. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707781058869 · Cited by 49 · see citing works
Using a preclinical mouse model of high-grade astrocytoma to optimize p53 restoration therapy
Shchors, K., Persson, A. I., Rostker, F., Tihan, T., Lyubynska, N., Li, N., Swigart, L. B., Berger, M. S., Hanahan, D., Weiss, W. A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219142110 · Cited by 48 · see citing works
Watanabe, T., Katayama, Y., Yoshino, A., Komine, C., & Yokoyama, T. (2003) · PubMed · Cited by 46 · see citing works
Kamiryo, T., Tada, K., Shiraishi, S., Shinojima, N., Nakamura, H., Kochi, M., Kuratsu, J., Saya, H., & Ushio, Y. (2002) · Journal of neurosurgery · doi:10.3171/jns.2002.96.5.0815 · Cited by 46 · see citing works
Adamson, D. C., Rasheed, B. A., McLendon, R. E., & Bigner, D. D. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0177 · Cited by 45 · see citing works
Hasan, M. K., Yaguchi, T., MINODA, Y., Hirano, T., Taira, K., Wadhwa, R., & Kaul, S. C. (2004) · Biochemical Journal · doi:10.1042/bj20040337 · Cited by 44 · see citing works
Astrocyte Differentiation States and Glioma Formation
Dai, C., & Holland, E. C. (2003) · The Cancer Journal · doi:10.1097/00130404-200303000-00002 · Cited by 45 · see citing works
Integrins and p53 pathways in glioblastoma resistance to temozolomide
Martin, S., Janoušková, H., & Dontenwill, M. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00157 · Cited by 43 · see citing works
Abnormalities of the ARF-p53 pathway in primary angiosarcomas of the liver
Weihrauch, M., Markwarth, A., Lehnert, G., Wittekind, C., Wrbitzky, R., & Tannapfel, A. (2002) · Human Pathology · doi:10.1053/hupa.2002.126880 · Cited by 44 · see citing works
Lassman, A. B. (2004) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-004-0043-3 · Cited by 44 · see citing works
Krex, D., Mohr, B., Appelt, H., Schackert, H. K., & Schackert, G. (2003) · Neurosurgery · doi:10.1227/01.neu.0000093426.29236.86 · Cited by 42 · see citing works
Merkel, C. A., Soares, R. B. D. S., de Carvalho, A. C. V., Zanatta, D. B., Bajgelman, M. C., Fratini, P., Costanzi-Strauss, E., & Strauss, B. E. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-316 · Cited by 43 · see citing works
Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma
Bradley, G., Irish, J., MacMillan, C., Mancer, K., Witterick, I., Hartwick, W. J., Gullane, P. J., Kamel‐Reid, S., & Benchimol, S. (2001) · Oncogene · doi:10.1038/sj.onc.1204131 · Cited by 41 · see citing works
Applications of mouse glioma models in preclinical trials
Hu, X., & Holland, E. C. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2004.08.023 · Cited by 40 · see citing works
Ushio, Y. (2003) · Frontiers in bioscience · doi:10.2741/865 · Cited by 41 · see citing works
PTEN: A potential prognostic marker in virus-induced hepatocellular carcinoma
Khalid, A., Hussain, T., Manzoor, S., Saalim, M., & Khaliq, S. (2017) · Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · doi:10.1177/1010428317705754 · Cited by 42 · see citing works
Oncolytic viruses for the therapy of brain tumors and other solid malignancies a review
Chiocca, E. A. (2003) · Frontiers in bioscience · doi:10.2741/976 · Cited by 38 · see citing works
Weber, A., Bellmann, U., Bootz, F., Wittekind, C., & Tannapfel, A. (2002) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-002-0637-6 · Cited by 37 · see citing works
Weber, A., Wittekind, C., & Tannapfel, A. (2003) · Pathology - Research and Practice · doi:10.1078/0344-0338-00435 · Cited by 37 · see citing works
Heme Oxygenase-1 in Central Nervous System Malignancies
Sferrazzo, G., Rosa, M. D., Barone, E., Volti, G. L., Musso, N., Tibullo, D., & Barbagallo, I. A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051562 · Cited by 36 · see citing works
p15 promoter methylation - A novel prognostic marker in glioblastoma patients
Urbschat (2009) · International Journal of Oncology · doi:10.3892/ijo_00000305 · Cited by 36 · see citing works
Gliomas: advances in molecular analysis and characterization
Boudreau, C. R., Yang, I., & Liau, L. M. (2005) · Surgical Neurology · doi:10.1016/j.surneu.2005.03.033 · Cited by 34 · see citing works
Genetically engineered mouse models of astrocytoma: GEMs in the rough?
Reilly, K. M., & Jacks, T. (2001) · Seminars in Cancer Biology · doi:10.1006/scbi.2000.0375 · Cited by 33 · see citing works
Prognostic Value of Mdm2, p53 and p16 in Patients with Astrocytomas
Ranuncolo, S. M., Varela, M. S., Morandi, A., Lastiri, J. M., Christiansen, S. B., Joffé, E. B. D. K., Pallotta, M. G., & Puricelli, L. (2004) · Journal of Neuro-Oncology · doi:10.1023/b:neon.0000027741.19213.99 · Cited by 32 · see citing works
The future role of personalized medicine in the treatment of glioblastoma multiforme
Adamson, C. (2010) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s6852 · Cited by 31 · see citing works
Korshunov, A., Голанов, А. В., & Timirgaz, V. (2001) · Acta Neuropathologica · doi:10.1007/s004010100379 · Cited by 31 · see citing works
Dai, C., & Holland, E. C. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00027-0 · Cited by 31 · see citing works
A Major Functional Difference between the Mouse and Human ARF Tumor Suppressor Proteins
Wadhwa, R., Sugihara, T., Hasan, M. K., Taira, K., Reddel, R. R., & Kaul, S. C. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203222200 · Cited by 31 · see citing works
Hussein, M. R., Ghorori, R. M. H. E., & El-Rahman, Y. G. A. (2006) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2006.00482.x · Cited by 28 · see citing works
Timmerman, D. M., Remmers, T. L., Hillenius, S., & Looijenga, L. H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105377 · Cited by 26 · see citing works
Stoczyńska-Fidelus, E., Piaskowski, S., Bieńkowski, M., Banaszczyk, M., Hułas-Bigoszewska, K., Winiecka-Klimek, M., Radomiak-Załuska, A., Och, W., Borowiec, M., Zięba, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087136 · Cited by 27 · see citing works
Kondo, I., Iida, S., Takagi, Y., & Sugihara, K. (2008) · Diseases of the Colon & Rectum · doi:10.1007/s10350-008-9382-5 · Cited by 27 · see citing works
Brain tumors: molecular biology and targeted therapies
Hegi, M. E., Murat, A., Lambiv, W. L., & Stupp, R. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl259 · Cited by 27 · see citing works
Self-citationPerturbations of the Ink4a/Arf gene locus in aflatoxin B1-induced mouse lung tumors
Tam, A. S. M. (2003) · Carcinogenesis · doi:10.1093/carcin/24.1.121 · Cited by 27 · see citing works
Ulanet, D., & Hanahan, D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012454 · Cited by 26 · see citing works
E2F activity is essential for survival of Myc-overexpressing human cancer cells
Santoni‐Rugiu, E., Duro, D., Farkas, T., Mathiasen, I. S., Jäättelä, M., Bártek, J., & Lukas, J. (2002) · Oncogene · doi:10.1038/sj.onc.1205828 · Cited by 24 · see citing works
Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets
Ghimenti, C., Fiano, V., Chiadò-Piat, L., Chiò, A., Cavalla, P., & Schiffer, D. (2003) · Journal of Neuro-Oncology · doi:10.1023/a:1022127302008 · Cited by 21 · see citing works
Ito, S., Ohga, T., Saeki, H., Watanabe, M., Kakeji, Y., Morita, M., Yamada, T., & Maehara, Y. (2007) · PubMed · Cited by 21 · see citing works
Ramaiah, M. J., Adusumilli, K., Chamarthy, S., & Angirekula, H. S. R. (2023) · Metabolic Brain Disease · doi:10.1007/s11011-023-01234-2 · Cited by 20 · see citing works
Saadatmandi, N., Tyler, T., Huang, Y., Haghighi, A. P., Frost, G., Borgström, P., & Gjerset, R. A. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700505 · Cited by 20 · see citing works
Silatecan DB-67 is a novel DNA topoisomerase I–targeted radiation sensitizer
Chen, A. Y., Shih, S., Garriques, L. N., Rothenberg, M. L., Hsiao, M., & Curran, D. P. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.317.4.2 · Cited by 19 · see citing works
INK4a-ARF alterations in liver cell adenoma
Tannapfel, A., Busse, C., Geiβler, F., Witzigmann, H., Hauss, J., & Wittekind, C. (2002) · Gut · doi:10.1136/gut.51.2.253 · Cited by 19 · see citing works
Molecular genetic analysis of deep-seated glioblastomas
Hayashi, Y., Yamashita, J., & Watanabe, T. (2004) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2003.12.010 · Cited by 18 · see citing works
Molecular genetic and proteomic analysis of synchronous malignant gliomas
Zhuang, Z., Lee, Y.-S., Zeng, W., Furuta, M., Vályi-Nagy, T., Johnson, M. D., Vnencak-Jones, C. L., Woltjer, R. L., & Weil, R. J. (2004) · Neurology · doi:10.1212/wnl.62.12.2316 · Cited by 17 · see citing works
Yoshioka, K., & Matsuno, Y. (2020) · Cancer Science · doi:10.1111/cas.14746 · Cited by 15 · see citing works
Liu, C., Zhang, H., Pan, Y., Huang, F., & Xia, S. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/24/8393 · Cited by 15 · see citing works
Wip1 over‐expression correlated with TP53/p14ARF pathway disruption in human astrocytomas
Wang, P., Rao, J., Yang, H., Zhao, H., & Yang, L. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.22004 · Cited by 14 · see citing works
Ton, T.-V. T., Hong, H. L., Devereux, T. R., Melnick, R. L., Sills, R. C., & Kim, Y. (2006) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2006.04.015 · Cited by 13 · see citing works
Delivery systems and molecular targets of mechanism-based therapies for GBM
Phuphanich, S., Brat, D. J., & Olson, J. J. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.4.649 · Cited by 12 · see citing works
Katara, R., Mir, R. A., Shukla, A. A., Tiwari, A., Singh, N., & Chauhan, S. S. (2010) · Biological Chemistry · doi:10.1515/bc.2010.103 · Cited by 12 · see citing works
KUB3 amplification and overexpression in human gliomas
Fischer, U., Hemmer, D., Heckel, D., Michel, A., Feiden, W., Steudel, W.-I., Hulsebos, T. J. M., & Meese, E. U. (2001) · Glia · doi:10.1002/glia.1090 · Cited by 12 · see citing works
Klein, M. A., Rüedi, D., Nozaki, M., Dell, E. W., Diserens, A., Seelentag, W. K. F., Janzer, R. C., Aguzzi, A., & Hegi, M. E. (2000) · Oncogene · doi:10.1038/sj.onc.1203941 · Cited by 11 · see citing works
Self-citationGenetic Alterations in Brain Tumors Following 1,3-Butadiene Exposure in B6C3F1 Mice
Kim, Y., Hong, H. L., Lachat, Y., Clayton, N. P., Devereux, T. R., Melnick, R. L., Hegi, M. E., & Sills, R. C. (2005) · Toxicologic Pathology · doi:10.1080/01926230590922848 · Cited by 11 · see citing works
Self-citation
- Authors
- Fulci, G., Labuhn, M., Maier, D., Lachat, Y., Hausmann, O., Hegi, M. E., Janzer, R. C., Merlo, A., & Van Meir, E. G.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- University Hospital of Basel (CH)
- Venue
- Oncogene
- Published
- 2000-07-28
- Volume
- 19
- Issue
- 33
- Pages
- 3816-3822
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2069294039
- Cited by
- 146
- References
- 41
- Citations by year
- 2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 7 · 2019: 2 · 2018: 1 · 2017: 2 · 2016: 2 · 2015: 1 · 2014: 2 · 2013: 4 · 2012: 7
- FWCI
- 7.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- glioblastoma, TP53 mutation, INK4a/ARF locus, tumor suppressor, MDM2 overexpression, EGFR amplification, PTEN mutation, CDKN2A, loss of heterozygosity, p53 pathway
- MeSH terms
- Animals, Carrier Proteins, Glioblastoma, Humans, Nuclear Proteins, Phosphoric Monoester Hydrolases, Proteins, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Tumor Suppressor Protein p53, Mutagenesis, Gene Deletion, Cyclin-Dependent Kinase Inhibitor p16, Tumor Suppressor Proteins, Tumor Suppressor Protein p14ARF, PTEN Phosphohydrolase, Mice, Proto-Oncogene Proteins c-mdm2, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review